Delivering unique therapeutic and R&D monoclonal antibodies against membrane receptors and haptens

Generating highly specific monoclonal antibodies targeting complex transmembrane proteins, chemical drugs, steroids, small and cyclic peptides, neoepitopes, toxins, epigenetic modifications, and carbohydrates, thanks to the unique combination of SynAbs proprietary technologies.

"Application of Synabs technologies led to the raising of therapeutic anti-CD2 Siplizumab and its licensing to our company. This successful mAb is now part of AstraZeneca pipeline".

"For a project involving the development of innovative immunoassays againt a particular steroid, SynAbs rapidly came to the conclusion that only rat-LOU species could deliver the expected outcomes. This small molecule project has become a huge success for Immunodiagnostic Systems!"

"We chose to launch one hard program with SynAbs in order to develop an anti-post translational modifications antibody. Indeed, there was no existing available monoclonal antibody for that given modification as of today. We are delighted with the collaboration with Synabs! We got a purified antibody with a high specificity to the very methyl group ! They know what they are talking about and have considerable experience with antibody production. They are also very flexible and the communication flow is efficient as well.  As this program is a success, VolitionRx has initiated new ones"

"Kinetic and functional assays with Synabs rat mAbs in comparison to the best commercial mouse mAb anti-Valproic acid reference were conducted by Werfen. All rat mAbs demonstrate a better affinity compared to mouse mAb, a dose-response curve contrary to mouse mAb. SynAbs Clone#30 has the highest affinity for free Valproic Acid (lowest IC50 - 3.5µM) of the market!"